Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3899366 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP2D6CYP2C19HSD17B10OPRM1 | |
| SCHEMBL354619 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP2D6CYP2C19HSD17B10OPRM1 | |
| SCHEMBL3893895 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP2D6CYP2C19HSD17B10OPRM1 | |
| SCHEMBL4495715 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP2D6CYP2C19HSD17B10OPRM1 | |
| SCHEMBL174568 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP2D6CYP2C19HSD17B10OPRM1 | |
| SCHEMBL3908680 | 1.00 | ALDH1A1 (0.50) | ALDH1A1CYP2D6CYP2C19HSD17B10OPRM1 | |
| Hydrochloric Acid SCHEMBL7673673 | 0.99 | ALDH1A1 (0.49) | ALDH1A1CYP2D6CYP2C19HSD17B10OPRM1 | |
| Hydrochloric Acid SCHEMBL7673668 | 0.99 | ALDH1A1 (0.49) | ALDH1A1CYP2D6CYP2C19HSD17B10OPRM1 | |
| Cadaverine Tartrate SCHEMBL2551513 | 0.90 | LMNA (0.45) | ALDH1A1CYP2D6CYP2C19HSD17B10OPRM1 | |
| Cadaverine Tartrate SCHEMBL2551782 | 0.90 | LMNA (0.45) | ALDH1A1CYP2D6CYP2C19HSD17B10OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096347-A1 | NOVEL PROCESS FOR PREPARING HIGHLY PURE TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-04-18 | — | — | US | claimed |
| EP-2556048-A2 | NOVEL PROCESS FOR PREPARING HIGHLY PURE TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Actavis Group PTC EHF (IS) | 2013-02-13 | — | — | EP | claimed |
| WO-2011128784-A2 | NOVEL PROCESS FOR PREPARING HIGHLY PURE TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-10-20 | — | — | WO | claimed |
| EP-1633697-B1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 3-ARYL-BUTYL AMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-03-11 | — | — | EP | claimed |
| US-7417170-B2 | Process for the preparation of substituted 3-aryl-butylamine compounds | GRUENENTHAL GMBH (DE) | 2008-08-26 | — | — | US | claimed |
| US-20060194988-A1 | Process for the preparation of substitued 3-aryl-butylamine compounds | GRUENENTHAL GMBH | 2006-08-31 | — | — | US | claimed |
| EP-1633697-A1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 3-ARYL-BUTYL AMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-03-15 | — | — | EP | claimed |
| WO-2004108658-A1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 3-ARYL-BUTYL AMINE COMPOUNDS | Grünenthal GmbH (DE) | 2004-12-16 | — | — | WO | claimed |
| WO-2014005546-A1 | PREPARATION METHOD OF TAPENTADOL HYDROCHLORIDE AND COMPOUNDS FOR PREPARATION OF TAPENTADOL HYDROCHLORIDE | 江苏恩华药业股份有限公司 (CN) | 2014-01-09 | — | — | WO | disclosed |
| US-20130096347-A1 | NOVEL PROCESS FOR PREPARING HIGHLY PURE TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-04-18 | — | — | US | disclosed |
| US-20130096347-A1 | NOVEL PROCESS FOR PREPARING HIGHLY PURE TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-04-18 | — | — | US | disclosed |
| US-20130096347-A1 | NOVEL PROCESS FOR PREPARING HIGHLY PURE TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-04-18 | — | — | US | disclosed |
| EP-2556048-A2 | NOVEL PROCESS FOR PREPARING HIGHLY PURE TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Actavis Group PTC EHF (IS) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011128784-A2 | NOVEL PROCESS FOR PREPARING HIGHLY PURE TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011128784-A2 | NOVEL PROCESS FOR PREPARING HIGHLY PURE TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-10-20 | — | — | WO | disclosed |
| EP-1633697-B1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 3-ARYL-BUTYL AMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-7417170-B2 | Process for the preparation of substituted 3-aryl-butylamine compounds | GRUENENTHAL GMBH (DE) | 2008-08-26 | — | — | US | disclosed |
| US-20060194988-A1 | Process for the preparation of substitued 3-aryl-butylamine compounds | GRUENENTHAL GMBH | 2006-08-31 | — | — | US | disclosed |
| EP-1633697-A1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 3-ARYL-BUTYL AMINE COMPOUNDS | Grünenthal GmbH (DE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004108658-A1 | METHOD FOR THE PRODUCTION OF SUBSTITUTED 3-ARYL-BUTYL AMINE COMPOUNDS | Grünenthal GmbH (DE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194988-A1 | Process for the preparation of substitued 3-aryl-butylamine compounds | BRD3, TYR, BBOX1 | ALDH1A1 543/4885CYP2D6 134/4885CYP2C19 467/4885 |
| US-20130096347-A1 | NOVEL PROCESS FOR PREPARING HIGHLY PURE TAPENTADOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TPMT, OPRD1, COMT | ALDH1A1 681/4885CYP2D6 94/4885CYP2C19 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.